Cytek Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
Cytek Biosciences, Inc. filed a Current Report on Form 8-K dated July 27, 2021, in connection with the closing of its initial public offering and related corporate governance changes. The company’s common stock trades on the Nasdaq Global Select Market under the symbol CTKB. The filing identifies Cytek as an emerging growth company.
Key Financial and Capital Markets Information
- The IPO consisted of 14,564,635 shares of common stock priced at $17.00 per share.
- The filing reports gross IPO proceeds of $200 million before underwriting discounts and commissions and offering expenses.
- Cytek issued and sold 11,764,706 shares.
- Selling stockholders sold 2,799,929 shares; proceeds from these shares were not proceeds to Cytek.
- The filing does not provide revenue, net income, operating cash flow, margins, debt, cash balances, liquidity measures, or post-IPO capitalization.
Material Changes and Corporate Actions
- On July 27, 2021, Cytek filed an amended and restated certificate of incorporation with the Delaware Secretary of State.
- Effective the same date, Cytek adopted amended and restated bylaws.
- The certificate and bylaws had previously been approved by the board and stockholders and became effective upon the IPO closing.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management forecast, or discussion of business risks. It reports the IPO closing and related governance actions but does not provide a reconciliation of gross proceeds to net proceeds or disclose the company’s use of proceeds.
Key Facts for Investor Verification
- Verify the final IPO prospectus for net proceeds after underwriting discounts, commissions, and offering expenses.
- Confirm the allocation of proceeds between Cytek and the selling stockholders.
- Review the amended and restated certificate of incorporation and bylaws filed as Exhibits 3.1 and 3.2.
- Review subsequent filings for the company’s post-IPO cash balance, use of proceeds, capitalization, debt, and operating results.